Abstract | BACKGROUND: STUDY DESIGN: Thirty infants (n = 10/arm) ≥36 wk gestation undergoing therapeutic hypothermia for NE were randomized to receive placebo, Darbe low dose (2 μg/kg), or high dose (10 μg/kg) given intravenously within 12 h of birth (first dose/ hypothermia condition) and at 7 d (second dose/normothermia condition). Adverse events were documented for 1 mo. Serum samples were obtained to characterize Darbe pharmacokinetics. RESULTS: Adverse events ( hypotension, altered liver and renal function, seizures, and death) were similar to placebo and historical controls. Following the first Darbe dose at 2 and 10 μg/kg, t(1/2) was 24 and 32 h, and the area under the curve (AUC(inf)) was 26,555 and 180,886 h*mU/ml*, respectively. In addition, clearance was not significantly different between the doses (0.05 and 0.04 l/h). At 7 d, t(1/2) was 26 and 35 h, and AUC(inf) was 10,790 and 56,233 h*mU/ml*, respectively (*P < 0.01). CONCLUSION: Darbe combined with hypothermia has similar safety profile to placebo with pharmacokinetics sufficient for weekly administration.
|
Authors | Mariana C Baserga, Joanna C Beachy, Jessica K Roberts, Robert M Ward, Robert J DiGeronimo, William F Walsh, Robin K Ohls, Jennifer Anderson, Dennis E Mayock, Sandra E Juul, Robert D Christensen, Manndi C Loertscher, Chris Stockmann, Catherine M T Sherwin, Michael G Spigarelli, Bradley A Yoder |
Journal | Pediatric research
(Pediatr Res)
Vol. 78
Issue 3
Pg. 315-22
(Sep 2015)
ISSN: 1530-0447 [Electronic] United States |
PMID | 25996892
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Erythropoietin
- Darbepoetin alfa
|
Topics |
- Adolescent
- Adult
- Area Under Curve
- Brain Diseases
(drug therapy)
- Darbepoetin alfa
(pharmacokinetics, therapeutic use)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Erythropoietin
(therapeutic use)
- Female
- Humans
- Hypothermia
(drug therapy)
- Hypothermia, Induced
- Infant, Newborn
- Magnetic Resonance Imaging
- Male
- Young Adult
|